Newest studies

Association of Cortical Free Water With Brain Tau Tangle Load in the Alzheimer Disease Continuum

49/100 ✓ Peer-reviewed Biomarkers Neurology

Key finding: In AD-relevant regions, increased free water correlates with tau load independently of macrostructural metrics or amyloid load. +1 more finding

Full summary, score breakdown and related studies → Original source

Digital memory assessments and plasma pTau217 enable efficient preclinical Alzheimer's trials

64/100 ✓ Peer-reviewed Treatments The journal of prevention of Alzheimer's disease

Key finding: A brief DMA combined with plasma pTau217 identifies a subset of cognitively unimpaired, amyloid-positive older adults at highest risk for cognitive and biomarker progression. +1 more finding

• Biomarkers
• Treatments
• Early Stage

Full summary, score breakdown and related studies → Original source

Head-to-head comparison of plasma p-tau217 immunoassays for incipient Alzheimer's disease in community cohorts

60/100 ✓ Peer-reviewed Biomarkers Alzheimer's Research & Therapy

Key finding: 344 participants across two community cohorts (median ages 62 and 76) +3 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

Leucettinib-21 decreases dosage effects of DYRK1A in human trisomy 21 iPSC-derived neural cells

16/100 ⚠ Preprint — not yet peer-reviewed Down syndrome and Alzheimer's bioRxiv

Key finding: Our results demonstrate that Leucettinib-21, a potent and selective low-molecular weight pharmacological inhibitor of DYRK1A, decreases DYRK1A activity in human trisomy 21 neural progenitor cells and cortical neurons.

• Down Syndrome

Scored 21 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

Full summary, score breakdown and related studies → Original source

Association of Long-Term Air Pollution Exposure with Dementia-Related Neuropathologies at Autopsy in a Community-Based Cohort

16/100 ⚠ Preprint — not yet peer-reviewed Risk factors medRxiv

Key finding: Higher exposure to PM 2.5 was associated with cerebral arteriolosclerosis and atherosclerosis at death, consistent with the known vascular toxicity of this pollutant. +4 more findings

• Brain Biology
• Risk Factors

Scored 44 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

Full summary, score breakdown and related studies → Original source

Introduction to Supplement Issue: Sensory loss in Alzheimer's disease and related dementias

45/100 ✓ Peer-reviewed Risk factors Journal of Alzheimer's disease : JAD

Key finding: Together, this work highlights the significant opportunities to use sensory information and remediation for earlier diagnosis, treatment, and prevention of dementia.

• Lifestyle

Full summary, score breakdown and related studies → Original source

Ginkgo biloba for cognitive impairment and dementia

70/100 ✓ Peer-reviewed Treatments The Cochrane database of systematic reviews

Key finding: Main results We included 82 studies with 10,613 participants; 72 studies with 9783 participants provided extractable data. +4 more findings

Full summary, score breakdown and related studies → Original source

Targeting Amyloid Beta Aggregation and Neuroinflammation in Alzheimer’s Disease: Advances and Future Directions

44/100 ✓ Peer-reviewed Inflammation and the immune system Cells

Key finding: Natural products such as curcumin, resveratrol, Ginkgo biloba, epigallocatechin gallate (EGCG), crocin, ashwagandha, and cannabidiol (CBD) have shown promising activity in modulating Aβ aggregation and neuroinflammatory pathways, offering multi-target neuroprotective effects in preclinical studies. +4 more findings

• Brain Biology
• Treatments

Full summary, score breakdown and related studies → Original source

Biomarkers for Alzheimer's disease and mild cognitive impairment: Recent advances in task-based EEG

59/100 ✓ Peer-reviewed Mild cognitive impairment Journal of Alzheimer s Disease

Key finding: Given the irreversible nature of AD, early detection of cognitive impairment is critical for improving prognosis and facilitating timely interventions before individuals meet the clinical criteria for AD.ObjectiveThe objective of this review is to provide a comprehensive summary of recent advances in task-based electroencephalography (EEG), such as using attention and inhibitory control tasks, which has recently emerged as a promising non-invasive biomarker for assessing neurophysiological alterations associated with AD and mild cognitive impairment (MCI).MethodsThis systematic review evaluates the efficacy of task-based EEG biomarkers in distinguishing cognitively impaired individuals from those without impairment. +1 more finding

• Early Stage
• Biomarkers

Full summary, score breakdown and related studies → Original source

Advances in Alzheimer’s disease diagnosis with machine learning and deep learning techniques: a comprehensive review

41/100 ✓ Peer-reviewed Digital health tools Artificial Intelligence Review

Key finding: Alzheimer’s disease (AD) is a chronic neurological disease and one of the main causes of dementia in around the world. +1 more finding

• Digital Tools
• Diagnosis

Full summary, score breakdown and related studies → Original source

Cognitive Impairment, Dementia and Depression in Older Adults

54/100 ✓ Peer-reviewed Brain tissue and pathology Journal of Clinical Medicine

Key finding: In a subset of older adults, new-onset depression-particularly when accompanied by executive dysfunction, subjective cognitive decline, or high white-matter hyperintensity burden-are associated with an increased likelihood of near-term cognitive decline and dementia, although evidence for a definitive prodromal state remains limited. +2 more findings

• Treatments
• Early Stage
• Other Dementias

Full summary, score breakdown and related studies → Original source

Failure of 18F-florbetapir Amyloid PET Imaging after Injection With an Automated Injector Using an Air-vent Filter for FDG Injection

29/100 ✓ Peer-reviewed Biomarkers Clinical Nuclear Medicine

Key finding: A 77-year-old woman with mild cognitive impairment was referred to 18F-florbetapir positron emission tomography (PET) to assess the indication of a disease-modifying drug against Alzheimer disease. +4 more findings

• Brain Scans

Full summary, score breakdown and related studies → Original source

Reduced Plasma Aβ Peptides but Stable NfL and GFAP in Major Depressive Disorder

55/100 ✓ Peer-reviewed Biomarkers International journal of molecular sciences

Key finding: Major depressive disorder (MDD) has been associated with an increased risk of cognitive decline and neurodegenerative disorders like Alzheimer's disease (AD), prompting interest in peripheral biomarkers related to amyloid metabolism as well as neuroaxonal and astroglial injury. +4 more findings

• Biomarkers
• Brain Biology

Full summary, score breakdown and related studies → Original source

Association of [ 18 F]Flortaucipir–PET and Plasma p-Tau217 With Tau Neuropathology in Alzheimer Disease and Other Neurodegenerative Disorders

58/100 ✓ Peer-reviewed Biomarkers Neurology

Key finding: Both markers identified Braak stage V-VI levels with similarly high performance (entorhinal SUVR, area under the curve [AUC] = 0.92 [95% CI 0.91-0.93]; temporal meta-ROI SUVR, AUC = 0.91 [95% CI 0.90-0.92]; plasma p-tau217, AUC = 0.90 [95% CI 0.89-0.91]), but PET outperformed plasma p-tau217 in identifying high/intermediate ADNCs (entorhinal ROI, AUC = 0.94 [95% CI 0.94-0.95]; temporal meta-ROI AUC = 0.94 [95% CI 0.94-0.95]; plasma p-tau217, AUC = 0.89 [95% CI 0.88-0.90]). +1 more finding

• Biomarkers
• Brain Scans
• Brain Biology

Full summary, score breakdown and related studies → Original source

Blood-Based Analysis of Different Tau Variants in Patients With Multiple Traumatic Injuries

55/100 ✓ Peer-reviewed Tau biomarkers JAMA network open

Key finding: With blood-based phosphorylated tau biomarkers soon to be used for diagnosis of Alzheimer disease, analyzing tau levels in other conditions could enhance biomarker interpretability. +3 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

A common 19 bp APOE enhancer deletion is protective against Alzheimer's disease in African Americans

57/100 ✓ Peer-reviewed Genetics Nature Communications

Key finding: The All of Us dataset confirms reduced Alzheimer´s disease risk associated with the deletion and identifies additional variants between APOE and APOC1 that disentangle APOE-ε4 neurological and lipid-related phenotypes. +1 more finding

• Genetics
• Prevention
• Health Equity

Full summary, score breakdown and related studies → Original source

Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial

86/100 ✓ Peer-reviewed Clinical trials The Lancet. Neurology

Key finding: 619 Colombian API registrants were prescreened, 315 were assessed for eligibility, and 252 were enrolled (crenezumab-carrier, n=85; placebo-carrier, n=84; placebo-non-carrier, n=83; 160 [63%] women and 92 [37%] men) between Dec 20, 2013, and Feb 27, 2017. 237 (94%) completed the trial, with final data collection on March 22, 2022. +4 more findings

• Clinical Trials
• Early Stage
• Side Effects

Full summary, score breakdown and related studies → Original source

Proteomics reveals three molecular subtypes of Alzheimer's disease with distinct progression patterns

73/100 ✓ Peer-reviewed Tau biomarkers Alzheimer's & dementia : the journal of the Alzheimer's Association

Key finding: Subtype 1, enriched in RNA metabolism pathways, showed the mildest atrophy and slowest cognitive decline. +4 more findings

Full summary, score breakdown and related studies → Original source

Risks of dementia and stroke in patients with hypertension using telmisartan or other renin‑angiotensin system inhibitors

59/100 ✓ Peer-reviewed Vascular contributions Alzheimer s & Dementia

Key finding: The telmisartan group had the lowest risk of all dementias (telmisartan vs NT-ARB: hazard ratio [HR]: 0.78; 95% confidence interval [CI]: 0.60 to 1.01; telmisartan vs angiotensin-converting enzyme inhibitor: HR: 0.67; 95% CI: 0.48 to 0.94). +4 more findings

• Risk Factors

Full summary, score breakdown and related studies → Original source

Retinal microvascular dysfunction in mild cognitive impairment: Associations with cerebral small vessel disease, plasma biomarkers, and cognitive decline

43/100 ✓ Peer-reviewed Vascular contributions Alzheimer s & Dementia

Key finding: MCI exhibited greater retinal tortuosity (p < 0.05) and sparser vasculature (p < 0.001), correlating with higher PSMD, WMH volumes, and adverse plasma biomarkers (all p < 0.05). +2 more findings

• Biomarkers
• Early Stage
• Other Dementias

Full summary, score breakdown and related studies → Original source

Urinary tract infection‐related delirium in Alzheimer's disease and related dementias: Clinical challenges and translational opportunities

37/100 ✓ Peer-reviewed Clinical safety Alzheimer s & Dementia

Key finding: Alzheimer's disease and related dementias (ADRD) affects millions of patients worldwide and is a leading cause of morbidity in older adults. +3 more findings

Full summary, score breakdown and related studies → Original source

Vulnerability of anterior cingulate Von Economo neurons to FTLD-tauopathies in behavioral variant frontotemporal dementia

34/100 ✓ Peer-reviewed Disease mechanisms Cerebral Cortex

Key finding: Wilcoxon rank-sum tests showed significantly lower VEN density in PiD than CBD (P < 0.05). +2 more findings

• Brain Biology
• Other Dementias

Full summary, score breakdown and related studies → Original source

Classification of tauopathies from human brain homogenates through salt‐modulated tau amplification

43/100 ✓ Peer-reviewed Disease mechanisms Alzheimer s & Dementia

Key finding: This method differentiated eight tauopathies, including Alzheimer's disease, Pick disease, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), argyrophilic grain disease (AGD), frontotemporal dementia with parkinsonism associated with chromosome 17 with N279K mutation (FTDP-17 N279K), and globular glial tauopathies types II and III. +4 more findings

Full summary, score breakdown and related studies → Original source

Glial cells in dementia: From cellular dysfunction to therapeutic frontiers

34/100 ✓ Peer-reviewed Inflammation and the immune system Cell Transplantation

Key finding: While prior reviews have cataloged glial dysfunction in isolation, this review offers a novel, integrative framework that maps the interconnected roles of glial subtypes across molecular, cellular, and circuit-level pathology in dementia. +4 more findings

• Brain Biology
• Treatments

Full summary, score breakdown and related studies → Original source

Association between leukocyte telomere length and neurodegenerative diseases: a prospective cohort in the UK Biobank

51/100 ✓ Peer-reviewed Long-term cohort studies Journal of Neurology

Key finding: Shorter LTL was associated with an increased risk of NDDs, including Alzheimer's disease (HR: 0.52, 95% CI 0.40-0.67, P < 0.001), dementia in AD (HR: 0.53, 95% CI 0.39-0.73, P < 0.001), unspecified dementia (HR: 0.74, 95% CI 0.58-0.95, P < 0.05), degenerative diseases of the nervous system (including other specified degenerative diseases such as circumscribed brain atrophy and senile degeneration of the brain) (HR: 0.62, 95% CI 0.45-0.84, P < 0.01), extrapyramidal and movement disorders (including other specified extrapyramidal and movement disorders such as a range of tremors, chorea, tics, and other abnormal involuntary movements) (HR: 0.63, 95% CI 0.48-0.82, P < 0.01), and mental and behavioral disorders due to use of alcohol (HR: 0.46, 95% CI 0.38-0.55, P < 0.001). +4 more findings

Full summary, score breakdown and related studies → Original source